Zhang X - Search Results

1

Development and validation of an LC-MS/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics.

Zhou S, Sha B, Wang L, Zhao Y, Wang Z, Zhang X, Han L, Shao F, Chen X. Zhou S, et al. Among authors: zhang x. Xenobiotica. 2023 Feb;53(2):84-92. doi: 10.1080/00498254.2023.2183367. Epub 2023 Mar 8. Xenobiotica. 2023. PMID: 36821249

2

Pictorial Imaging-Histopathology Correlation in a Rabbit with Hepatic VX2 Tumor Treated by Transarterial Vascular Disrupting Agent Administration.

He J, Liu C, Li T, Liu Y, Wang S, Zhang J, Chen L, Wang C, Feng Y, Floris G, Wang Z, Zhang X, Zhao L, Li Y, Shao H, Ni Y. He J, et al. Among authors: zhang j, zhang x. Int J Med Sci. 2020 Aug 25;17(15):2269-2275. doi: 10.7150/ijms.46165. eCollection 2020. Int J Med Sci. 2020. PMID: 32922191 Free PMC article.

3

SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.

Fan L, Wang C, Zhao L, Wang Z, Zhang X, Liu X, Cao L, Xu W, Li J. Fan L, et al. Among authors: zhang x. Neoplasia. 2020 Dec;22(12):714-724. doi: 10.1016/j.neo.2020.10.004. Epub 2020 Oct 23. Neoplasia. 2020. PMID: 33142237 Free PMC article.

4

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.

Han L, Zhang X, Wang Z, Zhang X, Zhao L, Fu W, Liang X, Zhang Z, Wang Y. Han L, et al. Among authors: zhang z, zhang x. Front Pharmacol. 2021 Apr 27;12:665253. doi: 10.3389/fphar.2021.665253. eCollection 2021. Front Pharmacol. 2021. PMID: 33986687 Free PMC article.

5

C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma.

Yang M, Su Y, Wang Z, Du D, Wei S, Liao Z, Zhang Q, Zhao L, Zhang X, Han L, Jiang J, Zhan M, Sun L, Yuan S, Zhou Z. Yang M, et al. Among authors: zhang q, zhang x. Biochem Pharmacol. 2021 Aug;190:114641. doi: 10.1016/j.bcp.2021.114641. Epub 2021 May 30. Biochem Pharmacol. 2021. PMID: 34077738 Free article.

6

Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China.

Wang Z, Zhang Z, Li Y, Sun L, Peng D, Du D, Zhang X, Han L, Zhao L, Lu L, Du H, Yuan S, Zhan M. Wang Z, et al. Among authors: zhang z, zhang x. Acta Pharm Sin B. 2021 Jun;11(6):1526-1540. doi: 10.1016/j.apsb.2021.03.005. Epub 2021 Mar 9. Acta Pharm Sin B. 2021. PMID: 34221866 Free PMC article.

7

Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study.

Hua R, Kong F, Wen X, Xiong Q, Chen J, Meng C, Ma H, Tan Y, Huang Y, Jiang Y, Guan Y, Mao X, Wang J, Xin Y, Gao H, Xu B, Li C, Wu Q, Zhang X, Wang Z, Zhao L, Zhang Y, Li G, Niu J. Hua R, et al. Among authors: zhang x, zhang y. J Viral Hepat. 2022 Jun;29(6):455-464. doi: 10.1111/jvh.13650. Epub 2022 Apr 8. J Viral Hepat. 2022. PMID: 35080256 Clinical Trial.

8

Establishment and comparison of three novel methods for the determination of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) in human serum.

Chen L, Xiao Q, Zhang X, Yang J. Chen L, et al. Among authors: zhang x. J Pharm Biomed Anal. 2016 Mar 20;121:13-21. doi: 10.1016/j.jpba.2015.12.057. Epub 2016 Jan 3. J Pharm Biomed Anal. 2016. PMID: 26773535

9

Development and application of a physiologically based pharmacokinetic model for HPPH in rats and extrapolate to humans.

Chen L, Zhang X, Cao Q, Wu Y, Zhang T, Tong H, Wang X, Yang J. Chen L, et al. Among authors: zhang t, zhang x. Eur J Pharm Sci. 2019 Mar 1;129:68-78. doi: 10.1016/j.ejps.2018.12.014. Epub 2018 Dec 29. Eur J Pharm Sci. 2019. PMID: 30597205 Clinical Trial.

10

A Physiologically Based Pharmacokinetic Model for Studying the Biowaiver Risk of Biopharmaceutics Classification System Class I Drugs With Rapid Elimination: Dexketoprofen Trometamol Case Study.

Zhang X, Ye X, Hu K, Li W, Li W, Xiao Q, Chen L, Yang J. Zhang X, et al. Front Pharmacol. 2022 Feb 10;13:808456. doi: 10.3389/fphar.2022.808456. eCollection 2022. Front Pharmacol. 2022. PMID: 35273497 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

169,046 results

Search Page